+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ranibizumab"

Ranibizumab Market Report 2025 - Product Thumbnail Image

Ranibizumab Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
From
From
From
From
From
From
From
Wet Age-Related Macular Degeneration (Wet AMD) - Pipeline Insight, 2024 - Product Thumbnail Image

Wet Age-Related Macular Degeneration (Wet AMD) - Pipeline Insight, 2024

  • Clinical Trials
  • August 2024
  • 240 Pages
  • Global
From
Macular Degeneration Pipeline Analysis Report - Product Thumbnail Image

Macular Degeneration Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
From
From
Loading Indicator

Ranibizumab is a monoclonal antibody used to treat optical disorders such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO). It is administered as an intravitreal injection, and works by inhibiting the activity of vascular endothelial growth factor (VEGF), which is responsible for the growth of abnormal blood vessels in the eye. Ranibizumab is the first anti-VEGF drug approved by the US Food and Drug Administration (FDA) for the treatment of wet AMD, and is now widely used in the treatment of other optical disorders. Ranibizumab is available in both branded and generic forms, and is marketed by a number of pharmaceutical companies, including Novartis, Regeneron, Genentech, and Allergan. Show Less Read more